{
    "ticker": "BCAB",
    "name": "Bluebird Bio, Inc.",
    "description": "Bluebird Bio, Inc. is a biotechnology company focused on developing transformative gene therapies for serious genetic diseases and cancer. Founded in 1992, Bluebird aims to provide innovative treatments that can potentially cure genetic disorders by addressing the root cause of diseases at the genomic level. The company is well-known for its pioneering work in lentiviral gene therapy, which allows for the insertion of therapeutic genes into patients' cells. Bluebird's lead product candidates include therapies for conditions such as sickle cell disease and beta-thalassemia, as well as its innovative approach to treating multiple myeloma. The company's commitment to advancing the field of gene therapy is underscored by its robust pipeline and collaborations with leading research institutions and healthcare organizations. Bluebird Bio is dedicated to improving the lives of patients and their families, making significant strides in the fight against genetic disorders. The company is also engaged in developing technologies that enhance the efficiency and effectiveness of gene therapies, aiming to make these treatments accessible to a broader patient population. With a strong focus on patient-centric research and development, Bluebird Bio is poised to be a leader in the rapidly evolving landscape of gene therapy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1992",
    "website": "https://www.bluebirdbio.com",
    "ceo": "Andrew Obenshain",
    "social_media": {
        "twitter": "https://twitter.com/bluebirdbio",
        "linkedin": "https://www.linkedin.com/company/bluebird-bio/"
    },
    "investor_relations": "https://investors.bluebirdbio.com",
    "key_executives": [
        {
            "name": "Andrew Obenshain",
            "position": "CEO"
        },
        {
            "name": "Nick Leschly",
            "position": "Former CEO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "Zynteglo",
                "Skysona"
            ]
        },
        {
            "category": "Pipeline Candidates",
            "products": [
                "bb1111",
                "bb21217"
            ]
        }
    ],
    "seo": {
        "meta_title": "Bluebird Bio, Inc. | Innovative Gene Therapies",
        "meta_description": "Explore Bluebird Bio, Inc., a biotechnology leader in gene therapy for genetic diseases and cancer. Learn about their innovative therapies and commitment to patient care.",
        "keywords": [
            "Bluebird Bio",
            "Gene Therapy",
            "Biotechnology",
            "Sickle Cell Disease",
            "Beta-Thalassemia",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Bluebird Bio known for?",
            "answer": "Bluebird Bio is known for its innovative gene therapies aimed at treating serious genetic diseases and cancer."
        },
        {
            "question": "Who is the CEO of Bluebird Bio?",
            "answer": "Andrew Obenshain is the CEO of Bluebird Bio, Inc."
        },
        {
            "question": "Where is Bluebird Bio headquartered?",
            "answer": "Bluebird Bio is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Bluebird Bio's main products?",
            "answer": "Bluebird Bio's main products include Zynteglo and Skysona, along with various pipeline candidates."
        },
        {
            "question": "When was Bluebird Bio founded?",
            "answer": "Bluebird Bio was founded in 1992."
        }
    ],
    "competitors": [
        "CRSP",
        "SGMO",
        "EDIT"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "AMGN",
        "ALNY"
    ]
}